Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia

Trial Profile

A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2019

At a glance

  • Drugs Moxetumomab pasudotox (Primary)
  • Indications Hairy cell leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 04 Jun 2019 Results assessing pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 27 May 2019 This trial was completed in Spain, according to European Clinical Trials Database.
    • 21 May 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top